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Abstract 
Brazil currently contributes 42 % of all malaria cases reported in the Latin America and the Caribbean, a region where 
major progress towards malaria elimination has been achieved in recent years. In 2014, malaria burden in Brazil 
(143,910 microscopically confirmed cases and 41 malaria-related deaths) has reached its lowest levels in 35 years, 
Plasmodium falciparum is highly focal, and the geographic boundary of transmission has considerably shrunk. 
Transmission in Brazil remains entrenched in the Amazon Basin, which accounts for 99.5 % of the country’s malaria 
burden. This paper reviews major lessons learned from past and current malaria control policies in Brazil. A compre-
hensive discussion of the scientific and logistic challenges that may impact malaria elimination efforts in the country 
is presented in light of the launching of the Plan for Elimination of Malaria in Brazil in November 2015. Challenges for 
malaria elimination addressed include the high prevalence of symptomless and submicroscopic infections, emerging 
anti-malarial drug resistance in P. falciparum and Plasmodium vivax and the lack of safe anti-relapse drugs, the largely 
neglected burden of malaria in pregnancy, the need for better vector control strategies where Anopheles mosquitoes 
present a highly variable biting behaviour, human movement, the need for effective surveillance and tools to identify 
foci of infection in areas with low transmission, and the effects of environmental changes and climatic variability in 
transmission. Control actions launched in Brazil and results to come are likely to influence control programs in other 
countries in the Americas.
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Background
Malaria is endemic to 21 countries in the region of the 
Americas, with 389,390 laboratory-confirmed cases and 
87 malaria-related deaths reported to the Pan Ameri-
can Health Organization (PAHO) in 2014. Nearly 20  % 
of the local population is exposed to some risk of infec-
tion [1]. The region comprises eight of the 34 endemic 
countries worldwide with a national policy for malaria 
elimination—namely, Argentina, Costa Rica, El Salva-
dor, Dominican Republic, Mexico, Nicaragua, Panama, 
and Paraguay [2]; moreover, eighteen of the region’s 21 
malaria-endemic countries have expressed commitment 
towards malaria elimination. Fourteen malaria-endemic 
countries in the region are on track to achieve a 75  % 
reduction in their case incidence rates between 2000 and 
2015, as called for by the United Nations’ Millennium 
Development Goals target 6.C [1].
Brazil recorded a 76.8  % decrease in malaria inci-
dence between 2000 and 2014, and now contributes 
42  % of all malaria cases reported in the Americas [1]. 
Transmission remains entrenched in the Amazon Basin, 
which accounts for 99.5 % of the country’s malaria bur-
den. Here, past and current malaria control policies and 
achievements in Brazil are reviewed, and key scientific 
and logistic challenges for eliminating residual malaria in 
the Amazon are discussed.
A brief history of malaria control in Brazil
Malaria control in Brazil started effectively at the 
beginning of the twentieth century [3]. The first anti-
malaria campaign was implemented in 1905, during the 
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construction of the port of Santos in the southeastern 
State of São Paulo, by the well-known physician Carlos 
Chagas (who few years later described Chagas’ disease). 
An association between housing conditions and the trans-
mission of the disease was soon observed. Mosquito col-
lections inside the houses in the construction area were 
done every 8  days, screens installed in all windows, and 
in-house fumigation with sulphur adopted [4–6]. After a 
month, the daily number of malaria episodes decreased 
dramatically, with no new cases being observed after 
3 months [4]. It was the first time that a measure aimed 
at killing the adult mosquito was adopted for malaria con-
trol [7]. Its success originated the concept that malaria is 
a ‘household infection’ (a disease acquired mostly inside 
the houses), accepted worldwide a few decades later. This 
concept became the basis for interventions such as indoor 
residual spraying (IRS) and the use of bed nets.
Between 1923 and 1925, a team led by Mark Boyd ana-
lysed four malarious areas in Rio de Janeiro State in order 
to propose alternatives for malaria control according to 
their environmental characteristics and the available 
financial resources [3]. Engineering projects to promote 
environmental management, such as the construction of 
drainage systems and filling marshes, led to major reduc-
tions in malaria transmission in coastal areas of southeast 
Brazil in the 1920s and 1930s [8, 9].
In 1930, an African malaria vector (originally identified as 
Anopheles gambiae but later shown to be Anopheles arabi-
ensis [10]) was discovered in the Northeast of Brazil, most 
likely brought by a ship coming from Senegal, progressively 
spreading along the coast. In only 8 months in 1938–1939 
there were 150,000 cases of malaria, and 14,000 deaths 
[11]. With the support from the Rockefeller Foundation, a 
massive control operation was implemented at the end of 
1938. Approximately 4000 workers were employed during 
19  months of control. The costs of the operation reached 
US$1.8 million, 87 % financed by the Brazilian government. 
Measures of control included monthly house spraying, early 
case detection and rapid treatment, spraying of cars and 
trucks leaving or entering the endemic area, elimination of 
breeding sites, ditching of subsurface water areas, and use of 
chemical larvicides. In 1940, An. arabiensis had been elimi-
nated from Brazil [3, 12]. A similar campaign was repeated 
in Egypt in 1943–1944 [13]. These two successful campaigns 
inspired the eradication strategy that marked the World 
Health Organization (WHO) malaria agenda between 1955 
and 1969 [14, 15].
Large‑scale malaria control and attempted elimination 
(1940–1970)
In the early 1940s, two-thirds of Brazil’s 40 million 
inhabitants lived in malaria-endemic areas. Six to eight 
million infections, and 80,000 malaria-related deaths, 
were estimated to occur each year [16, 17]. At that time, 
nationwide anti-malarial campaigns were initiated, fol-
lowing the establishment of the National Malaria Service 
[18]. Large-scale house spraying with dichloro-diphenyl-
trichloroethane (DDT) started in 1947, after a few pilot 
studies in Amazonian cities since 1945 [18]. Over the 
next decade, DDT spraying was extended to two million 
houses (Fig. 1), with a dramatic effect on malaria trans-
mission. In 1957, only 250,000 malaria cases were esti-
mated to occur in a population of 62 million [17].
Brazil’s malaria map shrank considerably between 1950 
and 1970 (Fig. 2). Malaria was virtually eliminated in the 
Northeastern, Southeastern, and Southern regions of the 
country, as well as in most of the Center-West region. 
Malaria elimination efforts initiated in 1958 by the Work-
group for Malaria Control and Eradication were later 
scaled up by the Malaria Eradication Campaign, officially 
implemented in 1965 [17], adopting the Global Malaria 
Eradication Programme strategies of the WHO [19]. 
First, the DDT house-spraying programme, which had 
been declining since 1957, was strengthened to reach up 
to 6.5 million houses in the late 1960s (Fig. 1). During the 
attack phase, which involved the enactment of anti-larval, 
insecticidal, and anti-malarial measures for 3–5 years in 
order to interrupt malaria transmission, all houses in the 
endemic area should be periodically sprayed with DDT 
for 3–5 years. Moreover, routine active and passive case 
detection of febrile cases was implemented, with labora-
tory diagnosis followed by chloroquine (CQ) treatment 
and notification of 37,000–110,000 laboratory-confirmed 
infections each year over the 1960s (Fig. 3).
Fig. 1 Annual number of houses sprayed with dichloro-diphenyl-
trichloroethane (DDT) in Brazil between 1945 and 1997. Data for the 
years 1945–1959 and 1965–1986 were obtained from the Brazilian 
Institute of Geography and Statistics, available at: http://seculoxx.
ibge.gov.br/pt/populacionais-sociais-politicas-e-culturais/busca-por-
palavra-chave/saude/985-malaria. Data for the years 1960–1964 were 
extracted from PAHO/WHO reports [199]. Data for 1987–1997 were 
extracted from Loiola [52]
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In the 1950s, Brazil pioneered another initiative for 
malaria control in hard-to-reach populations: the use of 
CQ added to cooking salt as a chemoprophylaxis strat-
egy (Pinotti’s method) [20, 21]. Deployment of CQ-
medicated or “chloroquinized” salt became a major 
component of the malaria elimination strategy in Brazil 
(between 1959 and 1961), as well in Guyana, Tanzania, 
Ghana, and Indonesia (between 1959 and 1965) [22, 23]. 
Major concerns regarding this strategy included its effec-
tiveness, the risk of selecting CQ-resistant parasites, and 
changes in taste and colour of table salt depending on 
storage conditions [20, 23–25].
The smallest number of malaria cases ever recorded in 
the country (36,900) was registered in 1961 (Fig. 3). In 1970, 
52,469 infections were diagnosed in Brazil, 60 % of them in 
the Amazon Basin [16]. With 59.7 % of the country’s terri-
tory, the Amazon had only 4 % of Brazil’s 90 million inhab-
itants enumerated by the 1970 population census. However, 
the demographic composition of the Amazon started to 
change at a fast pace, following efforts to integrate the area 
with the rest of the country, which brought about major 
increases in malaria transmission [26, 27].
Resurgent malaria on the Amazon frontier (1970–1990)
Following the implementation of a military dictatorship 
in Brazil in 1964, political and military factors drove 
the ideals of national security and integration as part of 
larger geopolitical strategy [27, 28]. Road construction 
facilitated the implementation of mining, timber extrac-
tion, cattle ranching, and farming settlements in the 
Amazon. Waves of migrants, mostly from the malaria-
free South, Southeast and Northeast regions (and thus 
malaria naïve), responded to federal government incen-
tives: according to the 1980 census, the Amazonian states 
of Pará, Rondônia, Amazonas, Mato Grosso, Amapá, 
Acre, and Roraima received nearly one million immi-
grants during the 1970s [29].
Between 1970 and 1983, one-third of all farming settle-
ments opened by the National Institute for Land Reform 
(INCRA) in the Amazon were located in the State of Ron-
dônia [30]. While the whole population of the country 
experienced a yearly growth rate of 2.5 % during the 1970s, 
Rondônia registered an astonishing yearly growth rate of 
15 %, with even higher increases in the rural area [31, 32]. 
Population growth continued during the 1980s after the 
Northwest Region Integrated Development Programme 
(POLONOROESTE), launched in 1981, partly financed 
by the World Bank [33]. In addition, gold prospecting and 
mining activities in southern Pará State attracted a flood of 
migrants, dramatically increasing the population of remote 
areas with no health infrastructure [29]. As a result, from 
1980 to 1991, the country registered a population growth 
rate of 1.8 %, the states comprising the legal Amazon a rate 
of 3.25 %, and Rondônia’s population grew at 7.4 %.
The most important impacts of this massive human 
influx were significant environmental changes due to 
deforestation, and a dramatic increase in malaria inci-
dence [29, 34]. With regards to malaria, a new concept 
of “frontier malaria” was proposed to characterize trans-
mission in the Amazon [26, 35, 36]. Frontier malaria 
has a temporal pattern that can be summarized in three 
phases. First, the epidemic phase, marked by intense out-
breaks observed for about 3 years after initial settlement. 
Outbreaks result from a combination of factors that 
include deforestation, which creates or expands breed-
ing habitats of the main local malaria vector, Anopheles 
darlingi [37], close to colonists’ ramshackle houses in the 
fringes of the rainforest [38–40], lack of acquired immu-
nity among most of the settlers, precarious habitat condi-
tions that offered no protection against mosquitoes, and 
lack of adequate knowledge of the disease, among others. 
Second, the transition phase, characterized by gradual 
declines in malaria transmission observed over the fol-
lowing years, as the farming settlement becomes consoli-
dated, with less environmental changes, better structured 
communities, improved housing, and better access to 
healthcare [35, 41, 42]. Finally, in the endemic phase, 
malaria transmission reaches lower and stable levels. 
In this setting, P. falciparum typically predominates in 
newly opened settlements, being progressively replaced 
by P. vivax in later stages [26].
Fig. 2 Extension of the malaria endemic areas in Brazil in 1960 and 
2014. The figure shows how the malaria map in Brazil shrunk between 
1960 and 2014. Currently, transmission is virtually limited to the 
Amazon Basin, an area that covers 60 % of the Brazilian territory and 
houses 13.4 % of the country’s population. States that compose the 
Amazon region have their names written in uppercase. Data obtained 
from the National Malaria Prevention and Control Program, Ministry 
of Health of Brazil
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In addition to these environmental and demographic 
changes, the late 1970s and the 1980s were one of the 
most difficult periods in Brazil’s recent economic his-
tory. Annual inflation rate was 110 % in 1980, jumping to 
1783 % in 1989. All social indicators deteriorated during 
this period, including those related to basic health [43]. It 
was under this scenario that a tenfold increase in malaria 
incidence was observed between 1970 and 1985; in 1985 
two states in the Amazon, Rondônia and Pará, accounted 
for 73 % of all malaria cases [29]. On average, more than 
half a million cases were observed annually during the 
1990s, with a peak of 632.8 thousand cases in 1999.
Changes in malaria species distribution
Following the concept of frontier malaria, Fig.  3 shows 
marked temporal changes in the relative contribution 
of P. falciparum to the malaria burden in Brazil. Plas-
modium falciparum accounted for 12  % of all malaria 
infections diagnosed in Brazil in 1961, but this propor-
tion increased over the following years. Between 1966 
and 1973, and again between 1983 and 1989, similar pro-
portions of slide-confirmed P. falciparum and P. vivax 
infections were diagnosed countrywide. Because the 
transmission of P. vivax species maintained an upward 
trend in the 1990s, while that of P. falciparum declined 
steadily, the proportion of falciparum malaria cases 
decreased since then. Of note is the fact that malaria-
related deaths follow the same pattern as the contribution 
of falciparum malaria, and the decline in the proportion 
of falciparum cases was accompanied by a decline in the 
number of malaria-related deaths (Fig.  3). Plasmodium 
vivax now causes more than 84 % of all malaria infections 
diagnosed in Brazil. There is little documented transmis-
sion (less than 0.1 % of all cases) of Plasmodium malar-
iae countrywide, although molecular techniques have 
revealed the presence of this species in 9–12 % of malaria 
patients in selected settings [44, 45].
The recent predominance of P. vivax in Brazil may be 
partially explained by biologic features that render this 
species less responsive than P. falciparum to control 
strategies based solely on early diagnosis and prompt 
treatment of blood-stage infections. First, low-density 
P. vivax infections are common, especially in areas 
approaching elimination, making laboratory diagnosis 
particularly difficult [46]. Second, parasites may persist in 
human hosts for several months as hypnozoites, the dor-
mant liver stages that may eventually cause relapses [47].
Anti-malarial drugs that target both blood and liver 
stages are needed for the radical cure of vivax malaria, 
but primaquine (PQ), the only licensed anti-malarial with 
hypnozoitocidal activity, requires a relatively long treat-
ment course (7–14  days) and can cause severe hemoly-
sis in patients with glucose-6-phosphate dehydrogenase 
(G6PD) deficiency [48]. Furthermore, P. vivax trans-
mission is greatly facilitated by the early production 
of infective stages, mature gametocytes. In fact, most 
vivax malaria patients have gametocytaemia detected by 
microscopy by the time they seek treatment [49], and vir-
tually all P. vivax infections in Brazil, either symptomatic 
or asymptomatic, comprise gametocyte-specific pvs25 
gene transcripts detectable with sensitive molecular 
techniques [50].
Malaria control on the Amazon frontier
In 1989, the Ministry of Health of Brazil launched the 
Amazon Basin Malaria Control Programme (PCMAM) 
to reduce resurgent malaria transmission and prevent 
its spread to non-endemic areas [51]. PCMAM was in 
operation until mid-1996, and its main strategy (ear-
lier and more aggressive treatment of malaria cases to 
reduce transmission and mortality) had a clear short-
term impact. Overall malaria incidence decreased by 60 % 
between 1989 and 1996, with the proportion of P. falcipa-
rum infections decreasing from 47 to 29 %. The network 
of malaria diagnosis and treatment outposts was greatly 
expanded across the Amazon to provide a CQ treatment 
to all suspected cases until diagnostic test results became 
available, followed by quinine or mefloquine for slide-con-
firmed P. falciparum infections [51]. House spraying with 
DDT, however, had been gradually phased out since the 
early 1980s [18, 29, 52], and DDT was officially banned 
from public health use in Brazil in 1998 [53]. Of note is 
the improvement in the information system that in 1993 
gathered data from 98 % of the municipalities considered 
as having the potential for high malaria risk [51].
Fig. 3 Annual number of laboratory-confirmed malaria cases 
reported in Brazil from 1959 to 2014. The total number of cases, those 
due to Plasmodium falciparum, and the number of malaria-related 
deaths are shown. Data obtained from the National Malaria Preven-
tion and Control Programme, Ministry of Health of Brazil
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The gains associated with PCMAM were lost over the 
next few years, culminating with 637,000 microscopi-
cally confirmed malaria cases recorded in 1999 (Fig.  3). 
As a consequence, in 2000 the Ministry of Health imple-
mented a comprehensive plan to reduce overall malaria 
incidence, severe morbidity and mortality, to eliminate 
malaria transmission in the urban area of state capi-
tals across the Amazon, and to prevent resurgence in 
malaria-free areas. The Intensification Plan of Malaria 
Control Activities in the Legal Amazon (PIACM) tar-
geted 254 municipalities (32.1  % of the total number of 
municipalities in the Amazon), which gathered 93.6  % 
of the malaria cases. The criteria for selection of those 
municipalities were: (i) those that had an annual parasite 
index (API) equal or greater than 50 cases per 1000 peo-
ple; (ii) those where P. falciparum malaria was respon-
sible for 20 % or more of the total number of cases; (iii) 
the capitals of the nine States that comprise the Amazon 
region; (iv) the set of municipalities that accounted for at 
least 80 % of all malaria cases in each State; and (v) those 
where urban malaria was observed [54]. Control meas-
ures were tailored to each specific epidemiological set-
ting. A 39 % reduction in malaria incidence, compared to 
1999, was achieved by the end of 2001.
In 2003, the Ministry of Health launched the National 
Malaria Prevention and Control Programme (NMPCP) 
with the goal to reduce incidence, mortality and severe 
malaria cases, to eliminate malaria from urban areas in 
the state capitals, and to prevent reintroduction of trans-
mission in areas where it had been interrupted [55]. 
While the goals of the NMPCP were broad, following the 
decentralization of the health system during the 1990s 
each municipality could adopt different control strate-
gies. For example, free-of-charge distribution of long-
lasting insecticide-treated bed nets (LLINs) started in the 
state of Acre in late 2006 [56], and was later expanded 
to all high-risk municipalities in the Amazon between 
2009 and 2011. In the early twenty first century, country-
wide malaria cases, severe morbidity, and lethality have 
decreased dramatically. In 2000, 615,247 cases were con-
firmed, with 21,288 hospitalizations and 243 deaths; in 
2013 there were 179,236 cases with 2365 hospitalizations 
and 41 deaths [16].
Currently, the Amazon Basin has nearly 27 million 
inhabitants (13.4 % of the total population of Brazil). In 
2014, 143,910 microscopically confirmed malaria cases 
and only 41 malaria-related deaths were recorded; this 
is the lowest incidence in 35  years (Fig.  3). About 60  % 
of all infections are diagnosed within 48 h after the onset 
of symptoms, preventing severe morbidity, and 16  % of 
the cases were identified through active case detection. 
Laboratory diagnosis of malaria by microscopy or rapid 
diagnostic tests (RDTs, which are mostly used in remote 
areas), is freely provided, being required for free treat-
ment. A network of nearly 3500 malaria outposts, 4900 
microscopists and 7900 health agents facilitate access 
to diagnosis and treatment even in remote communi-
ties. First-line treatments, provided at no cost in govern-
ment-run malaria outposts, are CQ-PQ for P. vivax, and 
an artemisinin combination therapy (ACT)—currently 
artemether–lumefantrine—plus a gametocidal dose of 
PQ for P. falciparum. Anti-malarial drugs are not avail-
able in the private sector.
Based on those achievements, in November 2015 Bra-
zil was awarded by PAHO the Malaria Champions of the 
Americas Award. In the same month, the NMCP of the 
Ministry of Health launched the Plan for Elimination 
of Malaria in Brazil. The plan is part of the Sustainable 
Development Goals [57] launched by the United Nations, 
with the goal to reduce the global number of cases by 
90  % until 2030, and to eventually eliminate malaria in 
35 countries. The Brazilian plan focuses on P. falciparum 
malaria, and provides guidelines to municipalities on 
diagnostics, treatment, vector control, and community 
sensitization and education [58, 59]. Next, several poten-
tial challenges that may impact the elimination efforts in 
Brazil are discussed.
Challenges for malaria elimination
Symptomless infections
The natural history of P. falciparum malaria has been 
well characterized in areas of high endemicity in Africa. 
Children have a primary malaria attack during their 
first year of life, while most toddlers and juveniles have 
already developed resistance against severe disease, but 
still experience a few clinical episodes. African adoles-
cents and adults, in contrast, are often clinically immune; 
they remain free of malaria symptoms despite continuous 
exposure to the parasite, but carry parasites throughout 
the transmission season. Life-long exposure to malaria 
parasites rarely leads to sterile immunity; low-density 
blood-stage infections remain detectable with molecular 
techniques, such as polymerase chain reaction (PCR), in 
all age groups. Nevertheless, little is known regarding the 
acquisition of clinical immunity to malaria in areas of less 
intense malaria transmission in Latin America.
One of the first reports of asymptomatic malaria infec-
tions in Brazil came from surveys by Avery-Jones and 
Ferreira Neto [60] in the costal belt of Santa Catarina 
State (Southern Region), where P. vivax was the domi-
nant species. In this typical “bromeliad-malaria” set-
ting covered by Atlantic rainforest (see below), the only 
known malaria vectors were Anopheles (Kerteszia) cruzi 
and Anopheles (K.) bellator, which breed in water trapped 
in bromeliad plants [61]. Using conventional microscopy, 
the investigators found 39 individuals to be parasitaemic 
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at one or more monthly house-to-house surveys, but only 
one of them had a malaria-related illness at the time of 
diagnosis. Asymptomatic parasite carriage persisted for 
up to 6  months. Moreover, nine symptomless relapses 
were diagnosed following CQ treatment of 13 sympto-
matic infections [60]. Similarly, low-density asympto-
matic P. vivax infections, some of them initially missed 
by conventional microscopy but indirectly diagnosed 
by serology [62, 63], have also been reported in other 
bromeliad-malaria settings in southeast Brazil [16]. Sub-
clinical infections were later described in Amazonians 
living in traditional riverine communities and exposed 
to malaria since birth [64–66]. These symptomless infec-
tions were found to be four to five times more prevalent 
than the symptomatic ones in riverine communities in 
Rondônia, with the risk for developing symptomatic 
malaria being inversely correlated with the subjects’ age 
[64].
In contrast, all malaria infections, even those with very 
low parasite densities, were thought to elicit clinical dis-
ease in malaria-naïve migrants settled on the Amazon 
frontier [67–70]. Molecular diagnosis, however, has often 
revealed entirely symptomless, low-density infections in 
migrant subjects living in typical frontier settlements in 
the Amazon [71–73]. For example, 56.6 % of all P. vivax 
infections diagnosed over 3  years in newly occupied 
farming settlements in Amazonas State were found to 
be asymptomatic; one-third of them were both submi-
croscopic (i.e., missed by microscopy) and asymptomatic 
[70]. Apparently healthy subjects accounted for half of 
the total P. vivax biomass found in the local population 
and nearly all asymptomatic P. vivax carriers had mature 
gametocytes detected with molecular techniques. Only 
17.0  % of the asymptomatic P. vivax carriers developed 
clinical symptoms over 6  weeks of follow-up, becoming 
detectable by routine surveillance of febrile illnesses [73]. 
Similar findings were reported during the follow-up of 
asymptomatic parasite carriers in another Amazonian 
settlement [74]. After five to 8 years of continuous expo-
sure to low/moderate levels of malaria transmission, the 
prevalence or incidence of both infection and malaria-
related disease decreased steadily among native Ama-
zonians and migrants, suggesting the acquisition of not 
only anti-disease immunity but also some degree of anti-
parasite immunity [65, 73].
The infectiousness of gametocytaemia in asymptomatic 
carriers remains largely unknown. Avery-Jones and Fer-
reira-Neto [60] suggested that even a small but constantly 
present number of symptomless individuals could result 
in a large number of infective man-days. Specifically, if 
four infective asymptomatic gametocyte carriers were 
present during all 365  days of the year, a total of 1460 
infective man-days would be observed. Similarly, if 10 
asymptomatic gametocyte carriers were present during 
all 365 days of the year, a total of 3650 infective man-days 
would be observed. However, assuming that individuals 
would remain infective for 6 days, and considering all 170 
laboratory-confirmed symptomatic malaria cases that 
had been diagnosed over a period of 12 months in their 
study site in Santa Catarina, only 1020 infective man-
days would be observed. Nevertheless, the infectiousness 
of asymptomatic carriers of low-grade parasitaemia to 
Amazonian malaria vectors remains understudied; one 
study described an infection rate of 1.2  % after feeding 
An. darlingi with blood from asymptomatic P. vivax car-
riers, and of 22 % for the mosquitoes fed with blood from 
symptomatic carriers [75].
With regards to control activities, the challenge is how 
to detect asymptomatic infections in order to minimize 
the number of new infections originating from them. 
Mass blood surveys can detect asymptomatic malaria, 
but as transmission declines large populations would 
have to be screened to diagnose relatively few asymp-
tomatic carriers, reducing the cost-effectiveness of this 
approach [60]. An alternative is to conduct reactive active 
case detection so that a confirmed malaria infection 
triggers the screening of individuals in a defined neigh-
bourhood [76]. Regardless of the detection strategy, the 
diagnostic techniques available for large-scale use, such 
as microscopy and RDT, may not be sensitive enough to 
detect low-grade infections that are typical of residual 
malaria settings [77].
A reactive active case detection strategy with sensi-
tive molecular diagnostic methods to detect new P. vivax 
infections in the neighbourhood of malaria cases diag-
nosed by routine surveillance (index cases) is currently 
being tested in Brazil. This strategy has been tailored for 
P. vivax infections, which tend to be maintained at low 
parasite densities and may relapse despite radical treat-
ment. Four case-detection rounds (0, 30, 60 and 180 days 
after the index case diagnosis) were carried out within a 
3 km radius around the index case to capture individuals 
during their primary infections and relapses. Molecular 
barcoding using single-nucleotide polymorphisms (SNPs) 
[78] or microsatellites [79] will facilitate the analysis of 
genetic relatedness between patient-derived P. vivax 
samples to elucidate malaria transmission networks.
Eliminating bromeliad malaria in southern Brazil
A small proportion (about 0.05 %) of all autochthonous 
malaria cases currently recorded in Brazil originate 
from areas along the Serra do Mar mountain range that 
extends across the states of Rio de Janeiro, Minas Gerais, 
Espírito Santo, São Paulo, Paraná, and Santa Catarina, in 
the Southeast and South regions, and is covered with by 
the Atlantic rainforest biome (Fig. 4) [16]. In these areas, 
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the main (or only) malaria vectors are An. cruzi and An. 
bellator, which breed in water trapped by the leaf axils 
of bromeliad plants that are particularly abundant in the 
Atlantic rainforest [61]. Initially called “forest malaria” 
[80], and later described as “bromeliad malaria” [81, 82], 
malaria transmitted by Kerteszia anophelines was his-
torically endemic in coastal areas of Southeast and South 
Brazil [83]. Bromeliad malaria is currently uncommon 
in most of the Atlantic forest biome of Brazil, but elimi-
nating residual transmission in remaining foci, which 
involve non-human primates as parasite reservoirs, has 
been a major challenge for several decades.
Only P. vivax and P. malariae infections are currently 
reported in humans in bromeliad malaria settings in 
Brazil, where monkeys of the genus Alouatta (howler 
monkeys) and Cebus (capuchin monkeys) are naturally 
infected with these malaria parasites and may represent 
major animal reservoirs of parasites [84]. However, P. fal-
ciparum was nearly as prevalent as P. vivax in bromeliad 
malaria areas of Santa Catarina State in the late 1940s 
[60]. Furthermore, P. falciparum infection was recently 
reported in An. cruzi vectors from São Paulo State [85], 
suggesting that Kerteszia anophelines may also transmit 
P. falciparum.
Bromeliad malaria constituted a major public health 
challenge in Santa Catarina, with over 26,000 laboratory-
confirmed infections diagnosed in 1947 in a population 
of 670,000 [60]. Local transmission of P. falciparum and 
P. malariae ceased in 1956 and 1961, respectively, as a 
result of control activities that included tree removal near 
major towns and replacement with eucalyptus trees (in 
which bromeliads do not grow) and vegetable/flowering 
plants, manual removal of bromeliad plants, intensive 
DDT spraying, and prompt diagnosis and CQ treatment 
of laboratory-confirmed infections [86, 87]. Neverthe-
less, P. vivax transmission persisted in the northern coast 
of Santa Catarina until the mid-1980s, where subpatent 
and asymptomatic human infections remained relatively 
common.
Prior to the molecular diagnosis era, serology was used 
to identify subjects with evidence of current or recent 
infections in bromeliad malaria foci along the coast of 
northern Santa Catarina [18]. In 1980–1982, over 20,000 
subjects living in endemic sites in the towns of São Fran-
cisco do Sul and Araquari had finger-prick blood samples 
spotted onto filter papers and examined for malarial anti-
bodies with the indirect fluorescent antibody test (IFAT), 
using P. vivax-infected red blood cells as capture anti-
gens. The nearly 500 subjects with antibody titers ≥64, 
regardless of clinical symptoms, received a full course 
of CQ and PQ. No further autochthonous malaria cases 
have been reported in these two towns since 1986 [86]. 
Similarly, over 11,000 samples were tested for antibod-
ies by IFAT in three consecutive population-based sur-
veys carried out between 1984 and 1984 in rural sites 
surrounding the town of Peruíbe, southern São Paulo. 
Overall, 146 (1.3  %) samples tested positive (antibody 
titers ≥ 16). The 70 (0.6 %) subjects with antibody titers 
≥64 were treated with CQ and PQ; 40 infections were 
further confirmed by thick-smear microscopy [63].
Interestingly, serology has the potential to detect not 
only ongoing blood-stage infections missed by conven-
tional microscopy [62], but also recent infections, either 
symptomatic or not, that might have led to P. vivax 
hypnozoite formation in the liver. Despite this poten-
tial, the use of serology for targeting asymptomatic car-
riers of hypnozoites and blood-stage infections in areas 
approaching P. vivax malaria elimination has been rarely 
reported.
Submicroscopic infections
Average parasite densities tend to decrease, with higher 
proportions of P. vivax infections being missed by 
microscopy but detected by PCR as malaria prevalence 
decreases in Amazonian communities [73]. Accordingly, 
between half and three-fourths of all PCR-diagnosed 
infections are typically missed by microscopy in hypo- 
and mesoendemic settings in Brazil [64, 65, 72, 73]. One-
fourth of all P. vivax infections diagnosed in one of these 
settings had densities <10 parasites per microlitre of 
blood [73], being likely to be missed even by experienced 
Fig. 4 Area covered by the Atlantic Forest biome in Brazil, where 
pockets of bromeliad-malaria transmission persist. The extension of 
the Atlantic forest biome was defined by a federal law in 2006. More 
than 60 % of the population lives in large urban centers located in 
the Atlantic forest biome, thus, of the original biome area (which 
represents 17.4 % of the Brazilian territory), only about 8 % remains 
as forest. States that compose the Amazon region have their names 
written in uppercase
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microscopists. Similarly, the proportion of P. falciparum 
infections that are submicroscopic but still detectable 
by nucleic acid amplification (NAA) increases in Africa, 
from 20  % in areas with the highest transmission to 
70–80 % in areas with the lowest transmission [88].
From a clinical perspective, these chronic, low-den-
sity infections may not be entirely harmless. For exam-
ple, subpatent parasitaemia has been associated with 
increased risk of anemia in riverine Amazonian popu-
lations [65]. From a public health perspective, the most 
important question is to what extent submicroscopic 
infections contribute to residual malaria transmission, 
arguing for the use of more sensitive diagnostic tech-
niques in the context of malaria elimination [89]. In 
low-prevalence settings in Africa, carriers of a submi-
croscopic P. falciparum parasitaemia were estimated to 
be the source of 20–50 % of all mosquito infections [88]. 
However, no comparable estimates are currently avail-
able for P. vivax in the Americas. Accordingly, WHO 
acknowledges the need for “more research to under-
stand better the contribution of submicroscopic infec-
tions in malaria transmission in low endemic settings and 
to identify which diagnostic strategies and NAA-based 
diagnostic techniques are most cost-effective in accel-
erating malaria elimination, compared to conventional 
malaria elimination methods” [89].
Serological tests that detect malaria-specific antibodies 
are currently unable to differentiate between recent and 
old infections. Therefore, they play no major role in rou-
tine case finding and management. However, in very low 
transmission settings serology helps to identify subjects 
who have been recently exposed to P. vivax and may still 
carry hypnozoites or even a low-grade (mostly asympto-
matic) asexual blood-stage parasitaemia, that are missed 
by microscopy [62, 63]. The bromeliad-malaria elimina-
tion campaigns in southern Brazil, as discussed before, 
illustrate how serology can be useful for targeting human 
reservoirs of P. vivax in areas of residual transmission. 
Moreover, in communities where malaria has been elimi-
nated, serology may help to identify resurgent malaria, 
especially when children and young adults, who were 
born after transmission was interrupted, are found to 
have specific antibodies.
Evolving Plasmodium falciparum anti‑malarial drug 
resistance
In 1825, physician José Maria Bomtempo reported that 
quinine was used indiscriminately and at very high dos-
ages in Rio de Janeiro [90]. Indeed, the first evidence of 
malaria parasite’s resistance to quinine came from Bra-
zil in the early 1900s. Arthur Neiva, in 1907, diagnosed 
malaria infections in individuals under compulsory 
prophylaxis with quinine (500  mg every 2 or 3  days) 
who worked in highly malarious marshlands 60 km away 
from Rio de Janeiro, the country’s capital at that time 
[91]. He thus recommended daily 500  mg doses of qui-
nine as the only effective chemoprophylaxis in that area 
[91]. Miguel Couto [92] reported the use of intravenous 
methylene blue to treat quinine-resistant malaria infec-
tions acquired in Rio de Janeiro as well as in the Ama-
zon, but he did not describe the quinine dose initially 
used. The finding by Oswaldo Cruz of quinine-resistant 
malaria among workers in the Madeira-Mamoré rail-
way construction site located in Rondônia state, western 
Amazon [93], was soon confirmed by Bernhard Nocht 
and Heinrich Werner, who documented quinine fail-
ures during the treatment of German workers returning 
from that region to Hamburg in 1910 [94]. Interestingly, 
despite these early reports, quinine remained widely used 
in Brazil until the mid-1990s, usually in association with 
tetracycline or doxycycline, to treat uncomplicated P. fal-
ciparum infections. Relatively little evidence of in  vitro 
[95, 96] or in vivo resistance to quinine [97, 98] has been 
published since then.
Emerging resistance to CQ and a fixed-dose sulfadox-
ine–pyrimethamine (SP) combination may have greatly 
contributed to explosive P. falciparum malaria outbreaks 
across the Amazon in the 1980s. The first report of CQ 
failure to clear P. falciparum infections in Brazil, pre-
sented at a national medical conference in 1954, drew 
relatively little attention [99], but later publications doc-
umented CQ resistance in Brazil [100, 101] and Colom-
bia [102] in the early 1960s. At least two CQ-resistant 
founder populations have been identified in this region, 
one circulating in the Amazon Basin of Brazil and Peru, 
and the second in Ecuador and Colombia [103]. CQ 
resistance became widespread across the Amazon Basin 
by the mid-1980s [104], when malaria cases were on the 
rise associated with colonization projects and environ-
mental changes in the region (Fig. 3).
SP had been available in Brazil since the 1960s to treat 
CQ-resistant falciparum malaria [105]. SP-resistant P. 
falciparum strains emerged within a few years, being first 
documented in the Centre-West region in 1972 [106]. By 
the end of the 1980s, SP failed to cure >90 % of P. falci-
parum infections in the Amazon [99], and since 1990, SP 
is no longer recommended for malaria chemotherapy in 
Brazil [99]. Before the introduction of ACT in 2006 [107], 
the first-line regimens for uncomplicated falciparum 
malaria recommended by the Ministry of Health of Bra-
zil were quinine plus doxycycline (formerly tetracycline) 
for 7 days or a single dose of mefloquine. Case reports of 
mefloquine (e.g., [108]) and quinine–tetracycline [e.g., 
109] failure in falciparum malaria have been published 
since then. The few clinical trials that evaluated the ther-
apeutic efficacy of these regimens reported cure rates 
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ranging between 98.9 [110] and 100  % [111] for meflo-
quine, and between 77.3 [98] and 100 % [97] for quinine 
plus tetracycline.
ACT has gradually replaced quinine–doxycycline and 
mefloquine as the first-line regimen for uncomplicated 
falciparum malaria in Brazil in the late 2000s. Nearly 
24,000 P. falciparum infections were treated with a fixed-
dose artesunate–mefloquine (ASMQ) combination in 
Juruá Valley, Acre, between July 2006 and December 
2008. Following this large-scale intervention, P. falcipa-
rum malaria incidence rates decreased substantially, with 
lower hospital admission rates, and a reduced propor-
tion of P. falciparum to P. vivax infections in this region 
[112]. A recently completed trial showed no evidence, 
either clinical or molecular, for emerging P. falciparum 
resistance to the fixed-dose ASMQ combination in Juruá 
Valley [113]. More data on ACT efficacy in other areas 
of Brazil are expected to be made publicly available by 
the Amazon Network for the Surveillance of Antima-
larial Drug Resistance (RAVREDA), a network organized 
in 2001 by the Amazonian countries of South America, 
with PAHO support, to respond to the challenge of anti-
malarial drug resistance in the region. RAVREDA oper-
ates in close association with the Amazonian Malaria 
Initiative (AMI), a partnership of the United States 
Agency for International Development with PAHO, the 
Centers for Disease Control and Prevention (CDC), the 
Management Sciences for Health’s Rational Pharmaceuti-
cal Management Plus (MSH/RPM Plus) programme, the 
United States Pharmacopoeia, and Links Media, Inc.
Resistance to artemisinin derivatives has not been 
documented in Brazil, but there is some concern that 
resistant parasites may circulate in areas of Suriname, 
Guyana and French Guyana bordering Brazil. Suriname 
has recently attracted a large number of immigrants, 
mainly from Brazil, to work in gold mines in the eastern 
and central parts of the country. An estimated 15,000 
(mostly illegal) miners currently live in settlements where 
health infrastructure and compliance with national 
malaria treatment policies are typically very poor [114]. 
A recent study in Suriname has documented a large pro-
portion (31 %) of P. falciparum-infected patients treated 
with artemether–lumefantrine who remained parasitae-
mic by day 3, consistent with some degree of artemether 
resistance in Suriname [115], although these findings 
have not been confirmed in other areas of the country. 
Nevertheless, Suriname is complying with WHO recom-
mendations for malaria control and P. falciparum malaria 
is now rarely diagnosed in the country [116]. In Guyana, 
the kelch propeller domain (k13) gene mutation C580Y, 
associated with artemisinin resistance, has been found 
in 5 % of 98 P. falciparum isolates analysed [117]. Inter-
estingly, an analysis of polymorphisms upstream and 
downstream the k13 gene suggest that the C580Y muta-
tion has emerged independently in Guyana and South-
east Asia [117]; these mutant parasites, however, did 
not have their drug sensitivity patterns analyzed so far. 
In French Guyana, up to 15,000 illegal gold prospectors 
live in high-endemic areas along with 30,000 legal resi-
dents. They typically use erratic ACT-based regimens, 
potentially including fake or substandard drugs, to treat 
P. falciparum infections, favouring the selection of drug-
resistant strains. Artemisinin resistance had not been 
characterized so far in French Guyana, but the country 
fails to comply with WHO recommendations for anti-
malarial treatment [116]. Therefore, unequal cross-bor-
der efforts to control malaria and contain the emergence 
of anti-malarial drug resistance pose potential threats to 
eliminate the disease from French Guyana, Brazil and 
Suriname [116].
Plasmodium vivax resistance to chloroquine
The global spread of CQ-resistant P. vivax strains [118] 
can further complicate malaria elimination efforts in 
Brazil. Radical cure of P. vivax malaria is achieved with 
25 mg/kg of CQ base over 3 days (maximum adult dose, 
1.5  g over 3  days), combined with a short hypnozoito-
cidal regimen of 0.5  mg/kg/day of PQ base (maximum 
daily dose, 30 mg/day) over 7 days in patients that weight 
under 70 kg. Since subtherapeutic PQ doses may lead to 
relapses in overweight patients [119], weight-adjusted PQ 
doses are now recommended in Brazil for patients over 
70 kg [120].
CQ-resistant vivax malaria has been reported in 
Colombia and Brazil since in the late 1980s, but anti-
malarial treatment had not been supervised, and drug 
levels were not measured, in these early studies [reviewed 
by 121]. The first solid evidence of CQ-resistant P. vivax 
infections in South America was published in 1996. Two 
Canadian patients returning from Guyana had received 
CQ and PQ, with therapeutic CQ levels documented at 
the time of parasite recurrence [122]. Further evidence 
of P. vivax resistance, confirmed by CQ level measure-
ments, originated from patients from Peru given CQ 
alone in 2003 [123]. Two studies described P. vivax resist-
ance to CQ in Manaus, the major port city in the Amazon 
Basin of Brazil, in the 2000s. The first study documented 
P. vivax recrudescence, despite adequate plasma levels of 
CQ, in 11 of 109 (10.1 %) patients treated with CQ alone 
who were followed up for 28 days [124]. The second study 
reported P. vivax recurrences in seven of 135 (5.2  %) 
patients treated with CQ and PQ who were followed 
up for 28 days; all of them had CQ levels above 100 ng/
mL of whole blood at the time of recurrence [125]. It 
remains to be determined whether CQ resistance has 
spread to other areas in Brazil; a very recent clinical trial 
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has detected little P. vivax resistance to CQ alone (2 %), 
and none to CQ–PQ combination, in major malaria hot-
spots in Juruá Valley (MUF, unpublished observations). 
Although ACT has been used to treat CQ-resistant P. 
vivax infections worldwide [126], its efficacy as an alter-
native to CQ remains unknown in Brazil.
The finding that PQ reverses CQ resistance in P. fal-
ciparum suggests that a similar effect might occur in P. 
vivax isolates simultaneously exposed to both drugs 
[reviewed by 127]. In fact, recent meta-analyses showed 
a lower efficacy of CQ alone against P. vivax asexual 
blood stages compared to CQ co-administered with PQ 
[118, 128]. Over the past 60 years, CQ and PQ have been 
routinely combined for the radical cure of P. vivax infec-
tions in most of South America, but not in Melanesia 
and Southeast Asia, where highly prevalent severe G6PD 
deficiency may lead to PQ-induced haemolysis. Indeed, 
CQ-resistant P. vivax emerged in regions where PQ is not 
widely used and remains less common in countries where 
CQ and PQ are routinely coadministered [118, 121], 
indicating that CQ–PQ combination therapy may have 
delayed the emergence of CQ-resistant P. vivax strains in 
selected settings.
PQ safety is an open question, since there is no prac-
tical, field-deployable rapid diagnosis test for G6PD 
deficiency screening prior to PQ administration [129]. 
Severe G6PD deficiency is uncommon across the Ama-
zon Basin [130, 131], but severe haemolysis has been 
occasionally reported following PQ treatment [132]. 
Moreover, PQ cannot be administered to pregnant and 
breastfeeding women and to children less than 6 months 
of age, because the risk of haemolysis. PQ efficacy also 
remains largely undetermined in Brazil. Relapse rates 
between 14.0 and 24.5 % have been described following 
supervised CQ–PQ treatment of imported P. vivax infec-
tions in non-endemic sites [119, 133]. Furthermore, an 
imported P. vivax infection acquired in Brazil was found 
to relapse despite the administration of 900  mg of PQ 
over 30 days [134]. The extent to which PQ metabolism 
in Amazonian populations is affected by polymorphisms 
in cytochrome P450 (CYP) family members, such as CYP 
2D6, remains unknown. In fact, reported failures of PQ 
may be partially associated with poor PQ metabolism 
in patients, rather than true drug resistance. However, 
the local monkey-adapted P. vivax strain Brazil I is PQ-
resistant in monkeys [135]. If PQ is failing in Brazil, for 
whatever reason, a substantial proportion of P. vivax 
infections may actually be relapses, placing improved 
anti-relapse treatment as a top research priority for guid-
ing malaria elimination in this country.
The finding that high-dose PQ regimens are safe and 
effective among G6PD-normal subjects led the US 
Centers for Disease Control and Prevention (CDC) to 
recommend 420 mg of PQ over 14 days as the standard 
anti-relapse regimen for adults in areas where standard 
PQ treatment fails [136]. WHO recommends a PQ dose 
of 0.5  mg/kg of body weight over 14  days to prevent 
relapses of infections acquired in Southeast Asia and 
Oceania [137], but this high-dose PQ regimen has not 
been evaluated in Brazil. Tafenoquine (TQ) is an alter-
native to PQ that requires shorter treatment regimens 
with improved compliance; a single dose of 300 mg TQ 
coadministered with CQ is effective to prevent P. vivax 
relapses in Brazil, Peru, India, and Thailand [138]. How-
ever, treatment with this long-lasting hypnozoitocidal 
drug does require prior screening for G6PD deficiency, 
an additional challenge due to the lack of a rapid screen-
ing test. Moreover, TQ is neither licensed nor available 
commercially in Brazil.
The hidden burden of malaria in pregnancy
Malaria infection during pregnancy is associated with 
substantial risks for the mother, her fetus, and the neo-
nate. Stillbirth, intrauterine growth retardation, prema-
turity, low birth weight, spontaneous abortion, increased 
neonatal and maternal mortality, and reduced neurocog-
nitive function later in childhood are documented com-
plications of malaria in pregnancy (MiP) [139, 140].
Between 6000 and 9000 microscopy-confirmed MiP 
cases are recorded in Brazil each year [141]. This repre-
sents 4–6 % of all malaria cases in the country. However, 
since conventional microscopy and RDTs fail to detect 
a substantial proportion of MiP episodes that are later 
diagnosed by PCR [142], these figures are likely to be 
underestimated. Health professionals involved in antena-
tal care, such as nurses and obstetricians, usually do not 
perceive MiP as a major preventable and treatable cause 
of morbidity in pregnant women and their offspring. This 
is partially due to the fact that infections with P. vivax are 
associated with less severe clinical consequences in preg-
nant women than those with P. falciparum, although an 
increased risk of low birth weight and anemia was docu-
mented in a large cohort study in Southeast Asia [143]. 
Erythrocytes parasitized with the former species do not 
sequester massively in placental capillaries [144, 145], 
but some placental changes associated with MiP, such 
as syncytial knotting and increased thickness of the pla-
cental barrier, have been recently documented in Brazil 
and may affect fetal growth [145, 146]. Because PQ can-
not be administered during pregnancy, relapses are com-
mon. Overall compliance with a weekly CQ regimen for 
suppressing relapses following P. vivax infection during 
pregnancy is usually poor in endemic areas of Brazil.
Almost one-third of the MiP cases recorded in Bra-
zil between 2003 and 2012 were due to P. falciparum, 
although this species accounted for only one-fourth of 
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the malaria burden in non-pregnant women during the 
same period [141]. Indeed, a cross-sectional survey of 
1699 febrile women at childbearing age found a signifi-
cantly greater P. falciparum to P. vivax ratio in pregnant 
women (1:2.3) than in their non-pregnant counterparts 
(1:5.6) living in Manaus, Brazil [147]. Also, a cohort study 
in the Peruvian Amazon found pregnant women to be 
twice more likely to have P. falciparum infections than 
non-pregnant women living in the same community, but 
no pregnancy-associated difference was found in the risk 
of P. vivax infections [148].
Pregnant women living in malaria-endemic areas of 
Brazil must be tested for malaria parasites at every ante-
natal care visit and receive supervised anti-malarial treat-
ment whenever MiP is confirmed [141]. In areas with 
stable transmission of P. falciparum in Africa, pregnant 
women are encouraged to sleep under insecticide treated 
bed nets (ITNs), and at least two doses of intermittent 
preventive treatment (IPTp) with SP should be adminis-
tered during antenatal care visits to prevent MiP [149]. 
Although sub-Saharan Africa has high rates of antenatal 
care attendance, current IPTp coverage is still low [150], 
despite the fact that IPTp-SP is highly cost-effective for 
prevention of MiP and reduction of neonatal mortality, 
even in areas with some molecular evidence of SP resist-
ance in P. falciparum populations [151]. Currently, there 
is no evidence to support the use of IPTp-SP to prevent 
MiP in areas with substantially lower levels of malaria 
transmission, such as those in Brazil.
Vector behaviour and control
Research conducted in the Amazon in 1931 showed 
that An. darlingi was found in much greater numbers 
indoors (endophilic) than outdoors (exophilic). Data 
collected between July 1942 and June 1946 in Rondônia 
(then called Guaporé territory) indicated that 93  % of 
the mosquitoes captured were present inside the houses. 
For the whole Amazon, this percentage was 88 % [152]. 
In 1977, another study showed that An. darlingi would 
enter houses that had been sprayed with DDT, but only 
to feed, and not to rest, as they would do in unsprayed 
houses [153]. Early records also show that An. darlingi 
was to some extent exophilic before the use of DDT 
[154]. Studies in Rondônia during the 1980s, however, 
found An. darlingi mainly outdoors, in the vicinity of 
houses [69, 153, 155, 156]. In addition to differences in 
biting location, An. darlingi also shows different patterns 
of peak biting time. For example, bimodal biting curves 
have been reported, with peaks in the early evening and 
at dawn, hours at which workers could be carrying out 
outdoor activities [156–158].
The exophilic behaviour is a point of discussion. Some 
argue that DDT use could have contributed to this 
transformation, selecting the exophilic strains to be more 
prevalent. Others consider that extensive deforestation 
and disorganized occupation could be indirectly respon-
sible for modifications in the mosquito behaviour, sub-
tracting its former sources of food (wild animals, who 
were scared away by the new settlers) and bringing man 
closer to its breeding places [3]. Population and muta-
tion differences have been documented in South Amer-
ica (where An. darlingi is the dominant vector), with a 
marked north–south divide [159]. Although chromo-
somal and isoenzymatic studies show a high degree of 
heterogeneity, no morphological characteristics for sepa-
ration of sub-species have been found [156].
This diversity in An. darlingi behaviour has important 
implications for vector control. First, an exophilic behav-
iour and peak biting times limit the impact that using 
ITNs could have in malaria transmission. Despite the evi-
dence on ITN effectiveness [160], no large scale trial of 
bed nets have been conducted in the Amazon. However, 
there is evidence that targeting ITNs to specific areas 
based on vector behaviour can be an important strategy 
to add to a package of interventions to reduce malaria 
transmission. Two studies conducted in specific areas 
in Venezuela and Colombia showed efficacy in ITNs to 
reduce malaria risk [161, 162]. In Brazil, LLINs impreg-
nated with permethrin were distributed across Juruá 
Valley (see Fig.  4) starting in late-2006 [163]. Although 
malaria incidence fell by 32 % over the next months, the 
intervention did not follow a systematic design to allow 
a proper impact evaluation, controlling for other ongo-
ing interventions. Also, two additional rounds of LLIN 
distribution (2010, 2014) led to little changes in malaria 
rates. Second, with regard to IRS, limiting factors include 
An. darlingi behaviour and the quality of houses, particu-
larly in rural areas—these are often made with poor con-
struction materials, with partial walls and no windows 
[56]. Although IRS was largely used in Brazil starting in 
the mid-1940s, during the first elimination campaign 
(Fig. 1), currently it is restricted to areas that match cer-
tain technical and operational requirements defined by 
the Ministry of Health [164]. Third, the use of larvicides 
is restricted to specific water habitats that can be easily 
identified and reached, such as fish ponds [165].
In summary, vector ecology and behaviour coupled 
with the local environmental conditions in the Amazon 
bring about major barriers for the adoption of large-scale 
vector control strategies. Indeed, in 2014, about 3  % of 
the population in the Amazon was covered by treated 
nets, and 1  % covered by IRS [166]. Yet, targeted inter-
ventions should be considered as important additions to 
a range of control strategies to reduce malaria transmis-
sion, as long as decisions are based on local knowledge of 
vector behaviour.
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Hitting foci of Plasmodium falciparum infection
Approximately 20,000 P. falciparum malaria cases were 
recorded in the Amazon Basin of Brazil in 2014. They 
were mostly restricted to ten high-risk areas, which 
account for three-fourths of the cases recorded coun-
trywide (Fig.  5). Four municipalities in Juruá Valley (in 
the Western portion of the Amazon, close to the border 
with Peru), with a combined population of nearly 120,000 
inhabitants, reported 46 % of all P. falciparum infections 
diagnosed in Brazil in 2014. The highly focal nature of P. 
falciparum malaria indicates that eliminating transmis-
sion of this species may be technically feasible by target-
ing a limited number of transmission pockets. Moreover, 
the potential of falciparum malaria for high morbidity 
and mortality and multidrug resistance, as well as its 
comparatively greater susceptibility to existing control 
measures, provide compelling arguments for prioritiz-
ing this species in malaria elimination strategies in Bra-
zil. Indeed, the recently launched Plan for Elimination of 
Malaria in Brazil devotes special attention to P. falcipa-
rum malaria, and has the ultimate goal of eliminating the 
disease by 2030 [167].
As argued for the Greater Mekong Subregion in Asia 
[168], the window of opportunity for P. falciparum elimi-
nation may be rather short. First, an elimination strategy 
must be implemented before widespread anti-malarial 
drug resistance (more specifically, resistance to arte-
misinin derivatives) makes P. falciparum infections in 
Brazil untreatable with currently available drugs. In other 
words, “multidrug resistance is both an impediment to 
elimination and a reason for pursuing it” [168]. Second, 
financing and political commitment to malaria elimina-
tion tends to wave once P. falciparum becomes widely 
perceived as a relatively minor public health problem and 
other competing priorities emerge countrywide.
Eliminating residual P. falciparum transmission will 
require a comprehensive assessment of the factors that 
favor malaria transmission in well-defined foci across 
the Amazon. Improved local knowledge regarding the 
relative contribution of vectors (e.g., species distribution, 
abundance, behaviour, and insecticide resistance), para-
sites (e.g., drug resistance and virulence), humans (e.g., 
behaviour, health infrastructure, and patterns of mobil-
ity), and the environment (e.g., land use and land change) 
to persisting P. falciparum transmission will be crucial, 
especially since underlying drivers of transmission are 
not likely to be same across foci. Indeed, human-made 
vector breeding sites (e.g., fish pounds opened for com-
mercial aquaculture) are a major factor leading to the 
current increase in P. falciparum malaria incidence in 
urban and peri-urban areas of Juruá Valley (Acre State, 
Western Amazon). Mining activities favor transmission 
in the outskirts of Itaituba (Pará State, Eastern Ama-
zon), while in Barcelos (northern Amazonas State, West-
ern Amazon) the majority of malaria cases is recorded 
in remote protected areas (mostly indigenous reserves). 
Finally, the main endemic sites in Lábrea (southern Ama-
zonas State) are newly opened farming settlements. Thus, 
different strategies will be needed for controlling and 
eventually eliminating P. falciparum in each area.
At present, there is no evidence that artemisinin-resist-
ant P. falciparum strains have been imported into Brazil. 
No data are available on anti-malarial drug resistance 
patterns of P. falciparum infecting Brazilians returning 
from mining camps in the Guiana Shield (a region com-
prising Guyana, French Guiana, Suriname and parts of 
Colombia, Venezuela and the northernmost tip of Brazil), 
where artemisinin resistance is suspected to be emerging 
[115].
Environmental changes
The natural environmental characteristics of the Amazon 
Basin offer suitable conditions for malaria transmission: 
temperature, humidity and the local vegetation guarantee 
a large population of vectors year-round, with less sea-
sonal variation when compared to other areas [26]. Also, 
the water level of rivers increases dramatically during the 
rainy season, flooding areas immediately proximal to the 
margins, and as the water level decreases with the ending 
of the rainy season, pools of water suitable for mosquito 
breeding proliferate [169].
Fig. 5 Current Plasmodium falciparum foci in Brazil. Municipalities 
indicated with circles in the map accounted for about 75 % of the 
laboratory-confirmed P. falciparum infections recorded in the Amazon 
in 2014. The circle sizes are proportional to the absolute number of 
cases in each municipality. Four high-risk municipalities (Cruzeiro do 
Sul, Mâncio Lima, Rodrigues Alves, and Guajará) are situated in Juruá 
Valley, westernmost Brazil, close to the border with Peru
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The massive deforestation observed in the Brazilian 
Amazon in the 1970s and 1980s brought about significant 
environmental changes and was associated with increases 
in malaria transmission, as previously discussed. In addi-
tion, large-scale development projects (e.g., road and dam 
construction) often produce environmental disturbances 
and social conditions that can be conducive to increases 
in vector-borne diseases, including malaria [170]. While 
expanding areas protected under environmental conser-
vation policies would be beneficial to prevent an increase 
in malaria transmission [171], current trends make it 
reasonable to expect that deforestation in the Amazon 
will continue to be a reason for concern [172] driven by 
varied economic pressures (e.g., cattle ranching, agricul-
ture, mining, and large-scale development projects). To 
mitigate some of those problems, since 2001 the Brazil-
ian legislation requires that, as part of the licensing of 
development projects located in malaria endemic areas, 
an evaluation should be conducted by the Ministry of 
Health [173].
Considered as the biggest global health threat of the 
twenty first century [174–176], climate change is likely 
to have an impact on malaria, despite contrasting results 
of global models [177–182]. Climatic effects on malaria 
can occur directly, through extreme events (e.g., drought, 
flooding), increases in average temperature, and changes 
in precipitation patterns, but also indirectly, by popula-
tion displacement, and water and food insecurity, which 
impact individuals’ exposure and vulnerability to infec-
tions. Despite the uncertainty embedded in climate 
change scenarios [183], it is expected that impacts on 
malaria will be observed, although the impacts and the 
responses are unlikely to be uniform across and within 
regions [184]. The magnitude of the impact will depend 
on: (i) temperature variability [185]; (ii) countries’ capac-
ity to anticipate future changes; (iii) adaptation strat-
egies adopted at varied scales; (iv) ongoing malaria 
control interventions; (v) the possibility that local char-
acteristics that affect malaria risk can be augmented by 
climatic changes; and (vi) the level of clinical immunity 
among the population [178]. Since 1996, more than a 
dozen atypical years (El Niño/La Niña), and at least one 
extreme drought not at all related to El Niño/La Niña, 
were observed in the Amazon. Yet, their potential effect 
on the patterns and level of malaria transmission remains 
largely unknown.
Deploying effective surveillance
Surveillance can be defined in different ways [186]. Con-
sidering it as an intervention through which data are sys-
tematically collected, analysed, and interpreted, so that 
both symptomatic and asymptomatic cases are identified, 
triggering quick action to prevent further transmission 
[187], then the main challenge is how to properly identify 
all the cases. Among the potential problems in achieving 
proper surveillance are human mobility, border issues, 
asymptomatic infections, and weak health and informa-
tion systems.
With respect to information systems, Brazil is in a priv-
ileged position. Since malaria is one of the diseases that 
require compulsory notification in the country, a national 
system gathers information on all malaria tests per-
formed across the country (microscopy and RDT), with 
demographic information on patients, and with detailed 
test results. Data are entered locally, and available real-
time at the municipal, state and federal levels.
Migratory movements have important malaria impli-
cations depending on the levels of immunity among 
migrants, the underlying patterns of transmission in 
sending and receiving areas, the local characteristics 
observed in areas of origin and destination, the individual 
knowledge about the disease, and the pattern of mobil-
ity [188, 189]. Human mobility is intense in the Brazil-
ian Amazon driven by new economic opportunities (e.g., 
mining, land availability) or by the need to obtain goods 
and/or services [190]. In a context of intense human 
mobility, the challenge of asymptomatic infections is 
likely to be augmented, since symptomless migrants 
represent a mobile and silent reservoir of malaria infec-
tions. Moreover, human movements can facilitate the 
reintroduction of malaria in areas that have significantly 
reduced (or even eliminated) malaria. Critically to that 
is when unequal control efforts are adopted by neigh-
bouring countries, potentially resulting in a high preva-
lence of imported cases near the borders [191, 192]. In 
that regard, one of the critical challenges in the Amazon 
region is the border between French Guiana, Suriname, 
and Brazil, where intense mobility (and importation of 
malaria cases) is fueled by gold mining in French Guiana 
and Suriname [116, 193].
Conclusion
The Plan for Elimination of Malaria in Brazil, launched 
in November 2015, is in alignment with the new Sustain-
able Development Agenda [194], and builds on a unique 
momentum: the number of malaria cases in the country 
has reached its lowest levels in 35 years, P. falciparum is 
highly focal, and the geographic boundary of transmis-
sion has considerably shrunk. While the prospects for 
success are good, challenges are many and varied. This 
paper discussed the challenges ahead, some already pre-
sent, others a possibility.
In light of the potential challenges, a few issues require 
some reflection. First, the promotion of collaboration 
between different government and private sectors (such 
as, for example, education, agriculture, finance, urban 
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planning, transportation, and environment), albeit often 
difficult to achieve, is of paramount importance to add a 
development dimension to malaria control [195]. Brazil 
has already promoted important initiatives in the con-
text of agrarian reform and infrastructure projects in 
areas suitable to malaria [196], but there is a need and an 
opportunity for additional collaborations.
Second, as malaria transmission continues to decline, 
guaranteeing resources for malaria interventions may 
clash with other pressing and emerging health priorities 
in the country. In that regard, history makes it very clear 
that malaria resurgence is a real possibility [197], and it 
should be avoided. Therefore, sustaining achieved gains, 
and moving towards further declines is the only option, 
and multisectoral collaboration can be an important ally 
in this task.
Third, individual risk perception of malaria and behav-
iour issues may affect the uptake of interventions and 
hamper the goals of elimination. Sensitizing individual 
and communities to maintain or adopt new behaviours 
that reduce the risk of infections is critically important as 
areas reach pre-elimination stages. New ways to promote 
behaviour change campaigns under scenarios of low 
transmission is an area that needs special attention [198].
Fourth, there is an increasing need for control measures 
that are tailored for P. vivax, the “last parasite standing”. 
Better strategies for relapse prevention in the presence of 
G6PD deficiency, and improved point-of-care laboratory 
diagnosis of low-level P. vivax parasitaemias are required. 
Helping to fill these knowledge gaps is an important con-
tribution that Brazilian researchers can provide to the 
current nationwide malaria elimination efforts.
The next 5 years will be critical for elimination goals in 
the Americas region. Successful outcomes of the malaria 
elimination plan that Brazil just launched will inspire 
and provide evidence for similar efforts in other coun-
tries. Eventual setbacks in the current trends in malaria 
transmission in Brazil may suggest the need to fine tune 
the proposed plan, and may shed light on unforeseen 
challenges to achieve elimination. How this chapter in 
the history of malaria control in Brazil will end is highly 
awaited by the malaria community.
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